SAN DIEGO -- The bioresorbable-polymer Orsiro stent continued to outperform the durable-polymer Xience in randomized data going out almost 2 years. Patients who got the Orsiro in the BIOFLOW V trial ...
Final 5-year follow-up from the BIOFLOW V trial continues to show advantages for the ultrathin-strut bioresorbable-polymer Orsiro DES (Biotronik) over the thin-strut, durable-polymer Xience (Abbott), ...
BÜLACH, Switzerland--(BUSINESS WIRE)--BIOTRONIK announced today the start of an international study comparing the company’s ORSIRO sirolimus-eluting coronary stent with Abbott Laboratory’s XIENCE ...
SAN DIEGO and BUELACH, Switzerland, Sept. 24, 2018 /PRNewswire/ -- Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiro a and Xience b drug-eluting stents ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “The final 5-year follow-up data confirms Orsiro’s ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with CAD who underwent PCI with an ultrathin, bioresorbable polymer sirolimus-eluting stent ...
BARCELONA, SPAIN —The biodegradable-polymer Orsiro sirolimus-eluting stent (Biotronik) proved superior to the durable-polymer Xience everolimus-eluting stent (Abbott Vascular) for 12-month target ...
BARCELONA, Spain—Among all the big trials airing results at the European Society of Cardiology (ESC) Congress 2017, one tiny stent—and its performance—could have slipped through the cracks. Earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results